Skip to content
Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
Chen MK.
FEBS J. 2021 Feb 11. doi: 10.1111/febs.15730. Epub ahead of print.
Molecular analyses of triple-negative breast cancer in the young and elderly.
Aine M, Boyaci C, Hartman J, Häkkinen J, Mitra S, Campos AB, Nimeus E, Ehinger A, Vallon-Christersson J, Borg Å, Staaf J.
Breast Cancer Res. 2021 Feb 10;23(1):20. doi: 10.1186/s13058-021-01392-0.
How to start niraparib in real-world Asian ovarian cancer patients?
Hong SH.
J Gynecol Oncol. 2021 Feb 8:e36. doi: 10.3802/jgo.2021.32.e36. Epub ahead of print.
Utilization, Timing, and Outcomes of BRCA Genetic Testing Among Women With Newly Diagnosed Breast Cancer From a National Commercially Insured Population: The ABOARD Study.
Armstrong J, Lynch K, Virgo KS, Schwartz MD, Friedman S, Dean M, Andrews JE, Bourquardez Clark E, Clasen J, Conaty J, Parrillo O, Sutphen R.
JCO Oncol Pract. 2021 Feb;17(2):e226-e235. doi: 10.1200/OP.20.00571.
Implementing Systematic Genetic Counseling and Multigene Germline Testing for Individuals With Pancreatic Cancer.
Chittenden A, Haraldsdottir S, Ukaegbu C, Underhill-Blazey M, Gaonkar S, Uno H, Brais LK, Perez K, Wolpin BM, Syngal S, Yurgelun MB.
JCO Oncol Pract. 2021 Feb;17(2):e236-e247. doi: 10.1200/OP.20.00678. Epub 2021 Jan 13.
Post navigation